Cardiac resynchronization therapy non-responder to responder conversion rate in the MORE-CRT MPP trial
Europace · 05.10.2023 · 25 (10)
DOI: 10.1093/europace/euad294 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Europace, online erschienen am 30.09.2023. Verfasst von Christophe Leclercq und 10 weiteren Autor:innen. Beteiligte Einrichtung: Service de Cardiologie et Maladies Vasculaires, Université de Rennes I, CICIT 804, CHU Pontchaillou Rennes, 2, rue Henri le Guilloux 35033 Rennes Céd…. Hauptthemen laut MEDLINE: Cardiac Resynchronization Therapy, Heart Failure. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Abbott.
Abstract (Originalsprache)
Aims
To assess the impact of MultiPoint™ Pacing (MPP) in cardiac resynchronization therapy (CRT) non-responders after 6 months of standard biventricular pacing (BiVP). Methods and results The trial enrolled 5850 patients who planned to receive a CRT device. The echocardiography core laboratory assessed CRT response before implant and after 6 months of BiVP; non-response to BiVP was defined as <15% relative reduction in left ventricular end-systolic volume (LVESV). Echocardiographic non-responders were randomized in a 1:1 ratio to receive MPP (541 patients) or continued BiVP (570 patients) for an additional 6 months and evaluated the conversion rate to the echocardiographic response. The characteristics of both groups at randomization were comparable. The percentage of non-responder patients who became responders to CRT therapy was 29.4% in the MPP arm and 30.4% in the BIVP arm (P = 0.743). In patients with ≥30 mm spacing between the two left ventricular pacing sites (MPP-AS), identified during the first phase as a potential beneficial subgroup, no significant difference in the conversion rate was observed.
Conclusion
Our trial shows that ∼30% of patients, who do not respond to CRT in the first 6 months, experience significant reverse remodelling in the following 6 months. This finding suggests that CRT benefit may be delayed or slowly incremental in a relevant proportion of patients and that the percentage of CRT responders may be higher than what has been described in short-/middle-term studies. MultiPoint™ Pacing does not improve CRT response in non-responders to BiVP, even with MPP-AS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Service de Cardiologie et Maladies Vasculaires, Université de Rennes I, CICIT 804, CHU Pontchaillou Rennes, 2, rue Henri le Guilloux 35033 Rennes Cédex 09, Rennes 35033, France.
- Departement of Cardiology, University of Geneva, Geneva, Switzerland.
- Isala Hospital, Department of Cardiology, Isala Klinieken, Zwolle, The Netherlands.
- King's College, London, UK.
- The Kerckhoff Heart and Thorax Center, Bad Nauheim, Kerckhoff Klinik, Bad Nauheim, Germany.
- Division of Cardiology, Policlinico Casilino, Rome, Italy.
ORCID-Profile: Christophe Leclercq, Haran Burri, Christopher A Rinaldi, Leonardo Calò, Joaquin Fernandez Concha
Förderung
- Abbott
Zitieren
APA
Leclercq, C., Burri, H., Delnoy, P. P., Rinaldi, C. A., Sperzel, J., Calò, L., Concha, J. F., Fusco, A., Al Samadi, F., Lee, K., & Thibault, B. (2023). Cardiac resynchronization therapy non-responder to responder conversion rate in the MORE-CRT MPP trial. Europace, 25(10). https://doi.org/10.1093/europace/euad294
Vancouver
Leclercq C, Burri H, Delnoy PP, Rinaldi CA, Sperzel J, Calò L, et al. Cardiac resynchronization therapy non-responder to responder conversion rate in the MORE-CRT MPP trial. Europace. 2023;25(10). doi:10.1093/europace/euad294
BibTeX
@article{Leclercq2023,
author = {Leclercq, Christophe and Burri, Haran and Delnoy, Peter Paul and Rinaldi, Christopher A and Sperzel, Johannes and Calò, Leonardo and Concha, Joaquin Fernandez and Fusco, Antonio and Al Samadi, Faisal and Lee, Kwangdeok and Thibault, Bernard},
title = {Cardiac resynchronization therapy non-responder to responder conversion rate in the MORE-CRT MPP trial},
journal = {Europace},
year = {2023},
volume = {25},
number = {10},
doi = {10.1093/europace/euad294}
}
EUVIMED